Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with chronic, plaque-type psoriasis for at least 6 months~* Must have moderate to severe psoriasis based on PASI greater than 12, IGA greater than 3, and greater than 10% body surface area~* Must be inadequately controlled by prior treatments (topicals, phototherapy, and/or systemic therapies)~Exclusion Criteria:~* Forms of psoriasis other than chronic, plaque-type (such as pustular, erythrodermic and guttate psoriasis)~* Drug induced psoriasis~* Use of other psoriasis treatments during the study~* Prior use of etanercept~* Prior use of secukinumab or any other drug that target IL-17 (interleukin 17) or the IL-17 receptor~* Pregnant or lactating women; women who do not agree to use contraception during the study and for 16 weeks after stopping treatment~* Significant medical problems such as uncontrolled high blood pressure, congestive heart failure, etc.~* History of an ongoing, chronic or recurrent infection or evidence of tuberculosis~* Allergy to rubber or latex~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AIN457 150mg (Type: EXPERIMENTAL): AIN457 150mg
- AIN457 300mg (Type: EXPERIMENTAL): AIN457 300mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Etanercept (Type: ACTIVE_COMPARATOR): Etanercept
- AIN457 150mg from Placebo (Type: EXPERIMENTAL): Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase
- AIN457 300mg from Placebo (Type: EXPERIMENTAL): Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase

Based on this trial design, predict the completion outcome and termination type (if applicable).